Accurate Wealth Management LLC Trims Position in Becton, Dickinson and Company $BDX

Accurate Wealth Management LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 80.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,472 shares of the medical instruments supplier’s stock after selling 10,006 shares during the quarter. Accurate Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $501,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Focus Financial Network Inc. grew its holdings in shares of Becton, Dickinson and Company by 2.2% during the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after acquiring an additional 58 shares during the period. Phillips Wealth Planners LLC lifted its stake in shares of Becton, Dickinson and Company by 2.7% in the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock valued at $430,000 after purchasing an additional 58 shares during the period. Union Bancaire Privee UBP SA boosted its position in shares of Becton, Dickinson and Company by 25.7% during the fourth quarter. Union Bancaire Privee UBP SA now owns 289 shares of the medical instruments supplier’s stock valued at $56,000 after purchasing an additional 59 shares in the last quarter. Legacy Solutions LLC boosted its position in shares of Becton, Dickinson and Company by 5.3% during the fourth quarter. Legacy Solutions LLC now owns 1,172 shares of the medical instruments supplier’s stock valued at $227,000 after purchasing an additional 59 shares in the last quarter. Finally, CX Institutional grew its stake in Becton, Dickinson and Company by 3.6% in the third quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 60 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. JPMorgan Chase & Co. lowered their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $191.62.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,713 shares of company stock worth $536,881 in the last 90 days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.0%

Shares of Becton, Dickinson and Company stock opened at $154.52 on Monday. The company has a 50-day simple moving average of $180.63 and a two-hundred day simple moving average of $187.60. The stock has a market capitalization of $44.00 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 11.20 and a beta of 0.24. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.